CSL Behring acquires Tucson biotech for $91 millionabout 1 hour ago


Biotherapeutics company CSL Behring in King of Prussia will buy Calimmune Inc. for at least $91 million to add an early-stage stem-cell gene therapy for sickle cell disease to its product pipeline. The Tucson-based biotechnology firm is working on a gene therapy and has two "platform" technologies to address challenges in the manufacturing and administration of gene- and stem-cell-based treatments, aligning with CSL Behring's expertise in hematology.



from Biotech News